항암제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 2020-2030년) - 약제 클래스별, 투여 경로별, 유통 채널별, 지역별 세분화 및 경쟁 구도
Oncology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1879194
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 항암제 시장은 2024년에 2,286억 5,000만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 13.33%로 성장하여 4,845억 4,000만 달러에 이를 것으로 예측됩니다.
항암제는 암의 예방, 진단, 치료를 위해 개발된 의약품으로 화학요법, 표적치료제, 면역요법 등 다양한 치료법을 포함하고 있습니다. 시장 성장은 주로 전 세계 암 발생률 증가, 고령화 사회로의 인구 통계학적 변화, 그리고 새로운 치료법 발견을 촉진하는 생명공학 연구 개발의 지속적인 발전에 의해 뒷받침되고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
2,286억 5,000만 달러
시장 규모 : 2030년
4,845억 4,000만 달러
CAGR : 2025-2030년
13.33%
성장 속도가 가장 빠른 부문
표적 치료제
최대 시장
북미
주요 시장 성장 촉진요인
주요 시장 과제
주요 시장 동향
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 항암제 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
약제 클래스별(세포 독성 약제, 표적 약제, 호르몬제, 기타)
투여 경로별(경구, 비경구, 기타)
유통경로별(병원 약국, 소매 약국, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 항암제 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 항암제 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 항암제 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 항암제 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트(UAE)
남아프리카공화국
제10장 남미의 항암제 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(M&A)
제품 출시
최근 동향
제13장 세계의 항암제 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Astellas Pharma Inc.
Pfizer, Inc.
Novartis AG
Astrazeneca Plc
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Amgen, Inc.
Bristol-Myers Squibb Company
Abbvie Inc.
Johnson & Johnson
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
The Global Oncology Drugs Market, valued at USD 228.65 Billion in 2024, is projected to experience a CAGR of 13.33% to reach USD 484.54 Billion by 2030. Oncology drugs are pharmaceutical agents developed for the prevention, diagnosis, and treatment of cancer, encompassing a diverse range of therapeutic modalities including chemotherapy, targeted therapies, and immunotherapies. The market's growth is primarily supported by the increasing global incidence of cancer, the demographic shift towards an aging population, and continuous advancements in biotechnological research and development driving the discovery of novel treatments.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 228.65 Billion
Market Size 2030
USD 484.54 Billion
CAGR 2025-2030
13.33%
Fastest Growing Segment
Targeted Drugs
Largest Market
North America
Key Market Drivers
The global oncology drugs market is significantly influenced by the increasing global cancer incidence. The rising prevalence of cancer worldwide, fueled by aging populations, lifestyle changes, and environmental factors, creates a substantial and continuously growing patient pool requiring advanced therapeutic interventions. This demographic shift directly translates into heightened demand for effective cancer treatments, necessitating a broader portfolio of pharmaceutical solutions. According to the World Health Organization and the International Agency for Research on Cancer, in their February 2024 report, an estimated 20 million new cancer cases occurred globally in 2022, underscoring the urgent and expanding need for oncology drugs.
Key Market Challenges
The extensive expenditure associated with oncology drug development and stringent regulatory approval processes presents a significant impediment to the growth of the Global Oncology Drugs Market. The substantial financial investment required for research, preclinical studies, and multiple phases of clinical trials, coupled with the high failure rate of experimental therapies, makes the development pathway costly and uncertain. This financial burden restricts the number of new treatments that can be brought to market, as companies must carefully prioritize projects with the highest likelihood of success and return on investment.
Key Market Trends
The rising integration of artificial intelligence in drug development profoundly reshapes the global oncology market by accelerating the discovery and development of novel therapies. AI algorithms streamline target identification, optimize lead compounds, and predict clinical outcomes, significantly reducing the timelines and costs associated with bringing new cancer treatments to market. This technological shift enhances research and development productivity. In April 2025, Tempus AI, Inc. announced strategic collaborations with AstraZeneca and Pathos AI, Inc. to build a multimodal foundation model in oncology, involving $200 million in data licensing and model development fees, highlighting investment in AI driven therapeutic advancements. According to the Pistoia Alliance's 2024 Lab of the Future report, AI was a top investment area for 62 percent of respondents over the next two years.
Key Market Players
Astellas Pharma Inc.
Pfizer, Inc.
Novartis AG
Astrazeneca Plc
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Amgen, Inc.
Bristol-Myers Squibb Company
Abbvie Inc.
Johnson & Johnson
Report Scope:
In this report, the Global Oncology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Oncology Drugs Market, By Drug Class:
Cytotoxic Drugs
Targeted Drugs
Hormonal Drugs
Others
Oncology Drugs Market, By Route of Administration:
Oral
Parenteral
Others
Oncology Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Oncology Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Oncology Drugs Market.
Available Customizations:
Global Oncology Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Oncology Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others)
5.2.2. By Route of Administration (Oral, Parenteral, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Oncology Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Route of Administration
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Oncology Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Oncology Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Oncology Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Distribution Channel
7. Europe Oncology Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Oncology Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Distribution Channel
7.3.2. France Oncology Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Oncology Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Oncology Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Oncology Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Distribution Channel
8. Asia Pacific Oncology Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Oncology Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Distribution Channel
8.3.2. India Oncology Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Oncology Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Oncology Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Oncology Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Oncology Drugs Market Outlook
